Cost-effectiveness of twice-daily indacaterol/glycopyrrolate inhalation powder for the treatment of moderate to severe COPD in the US

References

• Global Initiative for Chronic Obstructive Lung Disease (GOLD)Global strategy for the diagnosis, management and prevention of COPD2017 Available from: http://goldcopd.org/gold-2017-global-strategy-diagnosis-management-prevention-copd/Accessed February 28, 2018
   Google Scholar
• COPD Foundation COPD Statistics Across America – How Common Is COPD? Available from: https://www.copdfoundation.org/What-is-COPD/Understanding-COPD/Statistics.aspxAccessed March 20, 2018
   Google Scholar
• ManninoDMGagnonRCPettyTLLydickEObstructive lung disease and low lung function in adults in the United States: data from the National Health and Nutrition Examination Survey, 1988–1994Arch Intern Med2000160111683168910847262
   PubMed Web of Science ®Google Scholar
• National Center for Health Statistics (US)Health, United States, 2015 With special feature on racial and ethnic health disparities Available from: https://www.cdc.gov/nchs/data/hus/hus15.pdfAccessed November 14, 2018
   Google Scholar
• WheatonAGCunninghamTJFordESCroftJBCenters for Disease Control and Prevention (CDC)Employment and activity limitations among adults with chronic obstructive pulmonary disease-United States, 2013MMWR Morb Mortal Wkly Rep2015641128929525811677
   PubMed Web of Science ®Google Scholar
• FordESMurphyLBKhavjouOGilesWHHoltJBCroftJBTotal and state-specific medical and absenteeism costs of COPD among adults aged $18 years in the United States for 2010 and projections through 2020Chest20151471314525058738
   PubMed Web of Science ®Google Scholar
• HasegawaKTsugawaYTsaiCLBrownDFCamargoCAFrequent utilization of the emergency department for acute exacerbation of chronic obstructive pulmonary diseaseRespir Res2014154024717062
   PubMed Web of Science ®Google Scholar
• National Heart LaBIMorbidity & mortality: 2012 chart book on cardiovascular, lung, and blood diseases Available from: https://www.nhlbi.nih.gov/files/docs/research/2012_ChartBook_508.pdfAccessed May 3, 2015
   Google Scholar
• D’UrzoADRennardSIKerwinEMEfficacy and safety of fixed-dose combinations of aclidinium bromide/formoterol fumarate: the 24-week, randomized, placebo-controlled AUGMENT COPD studyRespir Res20141512325756831
   PubMed Web of Science ®Google Scholar
• Utibron Neohaler (indacterol and glycopyrrolate) [prescribing information]Marlborough, MASunovion Pharmaceuticals Inc2017
   Google Scholar
• MahlerDAKerwinEAyersTFLIGHT1 and FLIGHT2: Efficacy and safety of QVA149 (indacaterol/glycopyrrolate) versus its mono-components and placebo in patients with chronic obstructive pulmonary diseaseAm J Respir Crit Care Med201519291068107926177074
   PubMed Web of Science ®Google Scholar
• SiebertUAlagozOBayoumiAMState-transition modeling: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-3Value Health201215681282022999130
   PubMed Web of Science ®Google Scholar
• KerwinEFergusonGTSanjarSDual bronchodilation with indacaterol maleate/glycopyrronium bromide compared with umeclidinium bromide/vilanterol in patients with moderate-to-severe COPD: results from two randomized, controlled, cross-over studiesLung2017195673974728993871
   PubMed Web of Science ®Google Scholar
• FergusonGTKarpelJBennettNEffect of tiotropium and olo-daterol on symptoms and patient-reported outcomes in patients with COPD: results from four randomised, double-blind studiesNPJ Prim Care Respir Med2017271728154373
   PubMed Web of Science ®Google Scholar
• BuhlRGessnerCSchuermannWEfficacy and safety of once-daily QVA149 compared with the free combination of once-daily tiotropium plus twice-daily formoterol in patients with moderate-to-severe COPD (QUANTIFY): a randomised, non-inferiority studyThorax201570431131925677679
   PubMed Web of Science ®Google Scholar
• WilsonMRPatelJGColemanAMcdadeCLStanfordRHEarnshawSRCost-effectiveness analysis of umeclidinium/vilanterol for the management of patients with moderate to very severe COPD using an economic modelInt J Chron Obstruct Pulmon Dis201712997100828392684
   PubMed Web of Science ®Google Scholar
• Bevespi Aerosphere (glycopyrrolate/formoterol fumarate) [prescribing information]Wilmington, DEAstraZeneca Pharmaceuticals LP2016
   Google Scholar
• BorgSEricssonAWedzichaJA computer simulation model of the natural history and economic impact of chronic obstructive pulmonary diseaseValue Health20047215316715164805
   PubMed Web of Science ®Google Scholar
• CelliBRThomasNEAndersonJAEffect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH studyAm J Respir Crit Care Med2008178433233818511702
   PubMed Web of Science ®Google Scholar
• CopeSCapkun-NiggliGGaleRJardimJRJansenJPComparative efficacy of indacaterol 150 µg and 300 µg versus fixed-dose combinations of formoterol + budesonide or salmeterol + fluticasone for the treatment of chronic obstructive pulmonary disease – a network meta-analysisInt J Chron Obstruct Pulmon Dis2011632934421697997
   PubMed Web of Science ®Google Scholar
• DonohueJFMaleki-YazdiMRKilbrideSMehtaRKalbergCChurchAEfficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPDRespir Med2013107101538154623830094
   PubMed Web of Science ®Google Scholar
• DransfieldMTFeldmanGKorenblatPEfficacy and safety of once-daily fluticasone furoate/vilanterol (100/25 mcg) versus twice-daily fluticasone propionate/salmeterol (250/50 mcg) in COPD patientsRespir Med201410881171117924998880
   PubMed Web of Science ®Google Scholar
• EarnshawSRWilsonMRDalalAACost-effectiveness of fluticasone propionate/salmeterol (500/50 microg) in the treatment of COPDRespir Med20091031122119010652
   PubMed Web of Science ®Google Scholar
• HurstJRVestboJAnzuetoASusceptibility to exacerbation in chronic obstructive pulmonary diseaseN Engl J Med2010363121128113820843247
   PubMed Web of Science ®Google Scholar
• KarabisALindnerLMocarskiMHuismanEGreeningAComparative efficacy of aclidinium versus glycopyrronium and tiotropium, as maintenance treatment of moderate to severe COPD patients: a systematic review and network meta-analysisInt J Chron Obstruct Pulmon Dis2013840542324043936
   PubMed Web of Science ®Google Scholar
• MahlerDABairdJCAre you fluent in the language of dyspnea?Chest2008134347647718779189
   PubMed Web of Science ®Google Scholar
• Rutten-van MölkenMPOostenbrinkJBMiravitllesMMonzBUModelling the 5-year cost effectiveness of tiotropium, salmeterol and ipratropium for the treatment of chronic obstructive pulmonary disease in SpainEur J Health Econ20078212313517370096
   PubMed Web of Science ®Google Scholar
• SinghDFergusonGTBolitschekJTiotropium + olodaterol shows clinically meaningful improvements in quality of lifeRespir Med2015109101312131926320402
   PubMed Web of Science ®Google Scholar
• Centers for Medicare & Medicaid ServicesPhysician fee schedule Available from: http://www.cms.gov/apps/physician-fee-schedule/search/search-criteria.aspxAccessed May 10, 2018
   Google Scholar
• LlorCMoragasAHernándezSBayonaCMiravitllesMEfficacy of antibiotic therapy for acute exacerbations of mild to moderate chronic obstructive pulmonary diseaseAm J Respir Crit Care Med2012186871672322923662
   PubMed Web of Science ®Google Scholar
• OostenbrinkJBRutten-van MölkenMPMonzBUFitzgeraldJMProbabilistic Markov model to assess the cost-effectiveness of bronchodilator therapy in COPD patients in different countriesValue Health200581324615841892
   PubMed Web of Science ®Google Scholar
• PolskyDBonafedeMSuayaJAComorbidities as a driver of the excess costs of community-acquired pneumonia in U.S. commercially-insured working age adultsBMC Health Serv Res20121237923113880
   PubMed Web of Science ®Google Scholar
• Red Book OnlineTruven Health Analytics2017 Available from: https://truvenhealth.com/Products/Micromedex/Product-Suites/Clinical-Knowledge/RED-BOOKAccessed November 14, 2018
   Google Scholar
• StanfordRHShenYMclaughlinTCost of Chronic Obstructive Pulmonary Disease in the Emergency Department and Hospital: An Analysis of Administrative Data from 218 US HospitalsTreat Respir Med200655 534334916928147
   PubMedGoogle Scholar
• Spiriva Respimat (tiotropium bromide) [prescribing information]Ridgefield, CTBoehringer Ingelheim Pharmaceuticals, Inc2017
   Google Scholar
• Advair Diskus (fluticasone propionate and salmeterol inhalation powder) [prescribing information]Research Triangle Park NCGlaxoSmithKline; 2018
   Google Scholar
• Symbicort (budesonide and formoterol fumarate dihydrate) [prescribing information]Wilmington, DEAstraZeneca Pharmaceuticals2018
   Google Scholar
• Tudorza Pressair (aclidinium bromide inhalation powder) [prescribing information]Wilmington, DEAstraZeneca Pharmaceuticals2017
   Google Scholar
• Breo Ellipta (fluticasone furoate and vilanterol inhalation powder) [prescribing information]Research Triangle Park NCGlaxoSmithKline2017
   Google Scholar
• JonesPWGelhornHWilsonHResponder Analyses for Treatment Effects in COPD Using the St George’s Respiratory QuestionnaireChronic Obstr Pulm Dis20174212413128848921
   PubMed Web of Science ®Google Scholar
• Pharmacy Benefit Management InstitutePrescription Drug Benefit Cost and Plan Design Report 2015–20162015 Available from: https://www.pbmi.com/ItemDetail?iProductCode=2015-2016_BDR&Category=BDRAccessed November 14, 2018
   Google Scholar
• United States Bureau of Labor StatisticsConsumer Price Index AUCMCCU. All Urban Consumers. Medical Care ComponentUS Bureau of Labor StatisticsWashington, DC2012 Available from: http://data.bls.gov/cgibin/surveymost?cuAccessed February 10, 2017
   Google Scholar
• DuboisRWOptimal slices of the healthcare spending pie: can traditional comparative effectiveness research address resource allocation?J Comp Eff Res20165652552727618405
   PubMed Web of Science ®Google Scholar